AN2 Therapeutics, Inc. (ANTX)
$3.60-16.28%Close
SELLCRISIS · day 5
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $130M
- Beta
- -0.98
- P/E (TTM)
- -3.36
- Short % float
- 12.47%
- Days to cover
- 9.5
- SI change
- +4.0%
- 1W
- -28.99%
- 1M
- -34.07%
- vs SPY 1W
- -28.86%
- vs SPY 1M
- -36.57%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 6
- VALUE
- 5
- GROWTH
- 39
- GARP
- 0
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-32.1%
REV YoY-
ROE-53.5%
EPS YoY-
ROA-44.4%
GROSS0
OP0
NET0
[VALUATION]
P/E TTM-3.36
P/E FWD-
SECTOR PE20.34
INDUSTRY PE13.84
P/B2.12
P/FCF-
EV/EBITDA-2.27
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E-
ALTMAN Z-
CURR RATIO14.32
ND/EBITDA-
BETA-0.98
Company news
FAQ
- What is LOPJLB’s current signal on ANTX?
- LOPJLB’s latest quantitative signal on AN2 Therapeutics, Inc. (ANTX) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is ANTX in?
- AN2 Therapeutics, Inc. (ANTX) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does AN2 Therapeutics, Inc. (ANTX) do?
- AN2 Therapeutics, Inc. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of treatments for uncommon, long-term, and severe infectious conditions. A key focus of their pipeline is epetraborole, an investigational oral medication designed for once-daily administration to individuals battling chronic non-tuberculous mycobacterial lung disease.…